Journal of Clinical Oncology, Vol 15, 103-109, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Proposal for classifying the acute emetogenicity of cancer chemotherapy

PJ Hesketh, MG Kris, SM Grunberg, T Beck, JD Hainsworth, G Harker, MS Aapro, D Gandara and CM Lindley
St Elizabeth's Medical Center, Boston, MA 02135, USA. PhesKeth@aol.com

PURPOSE: To propose a classification of the acute emetogenicity of antineoplastic chemotherapy agents, and to develop an algorithm to define the emetogenicity of combination chemotherapy regimens. METHODS: A Medline search was conducted to identify (1) clinical trials that used chemotherapy as single-agent therapy, and (2) major reviews of antiemetic therapy. The search was limited to patients who received commonly used doses of chemotherapy agents, primarily by short (< 3 hours) intravenous infusions. Based on review of this information and our collective clinical experience, we assigned chemotherapy agents to one of five emetogenic levels by consensus. A preliminary algorithm to determine the emetogenicity of combination chemotherapy regimens was then designed by consensus. A final algorithm was developed after we analyzed a data base composed of patients treated on the placebo arms of four randomized antiemetic trials. RESULTS: Chemotherapy agents were divided into five levels: level 1 (< 10% of patients experience acute [< or = 24 hours after chemotherapy] emesis without antiemetic prophylaxis); level 2 (10% to 30%); level 3 (30% to 60%); level 4 (60% to 90%); and level 5 (> 90%). For combinations, the emetogenic level was determined by identifying the most emetogenic agent in the combination and then assessing the relative contribution of the other agents. The following rules apply: (1) level 1 agents do not contribute to the emetogenic level of a combination; (2) adding > or = one level 2 agent increases the emetogenicity of the combination by one level greater than the most emetogenic agent in the combination; and (3) adding level 3 or 4 agents increases the emetogenicity of the combination by one level per agent. CONCLUSION: The proposed classification schema provides a practical means to determine the emetogenic potential of individual chemotherapy agents and combination regimens during the 24 hours after administration. This system can serve as a framework for the development of antiemetic guidelines.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Yonemura, N. Katsumata, H. Hashimoto, S. Satake, M. Kaneko, Y. Kobayashi, A. Takashima, Y. Kato, M. Takeuchi, Y. Fujiwara, et al. Randomized Controlled Study Comparing Two Doses of Intravenous Granisetron (1 and 3 mg) for Acute Chemotherapy-induced Nausea and Vomiting in Cancer Patients: A Non-inferiority Trial Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 443 - 448. [Abstract] [Full Text] [PDF]

				A. Naeim, S. M. Dy, K. A. Lorenz, H. Sanati, A. Walling, and S. M. Asch Evidence-Based Recommendations for Cancer Nausea and Vomiting J. Clin. Oncol., August 10, 2008; 26(23): 3903 - 3910. [Abstract] [Full Text] [PDF]

				P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]

				S. Y. Barbour Caring for the treatment-experienced breast cancer patient: The pharmacist's role Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S16 - S22. [Abstract] [Full Text] [PDF]

				A. Georgy, J. Neceskas, and S. Goodin Antiemetic care for patients with breast cancer: Focus on drug interactions and safety concerns Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2227 - 2236. [Abstract] [Full Text] [PDF]

				S. Grunberg Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis Ann. Onc., February 1, 2007; 18(2): 233 - 240. [Abstract] [Full Text] [PDF]

				G. M Higa, M. L Auber, R. Altaha, D. Piktel, S. Kurian, G. Hobbs, and K. Landreth 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2006; 12(4): 201 - 209. [Abstract] [PDF]

				B. Bloechl-Daum, R. R. Deuson, P. Mavros, M. Hansen, and J. Herrstedt Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment J. Clin. Oncol., September 20, 2006; 24(27): 4472 - 4478. [Abstract] [Full Text] [PDF]

				M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]

				The Antiemetic Subcommittee of the Multinational A Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference Ann. Onc., January 1, 2006; 17(1): 20 - 28. [Abstract] [Full Text] [PDF]

				D. G. Warr, P. J. Hesketh, R. J. Gralla, H. B. Muss, J. Herrstedt, P. D. Eisenberg, H. Raftopoulos, S. M. Grunberg, M. Gabriel, A. Rodgers, et al. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2822 - 2830. [Abstract] [Full Text] [PDF]

				A. M Massaro and K. L Lenz Aprepitant: A Novel Antiemetic for Chemotherapy-Induced Nausea and Vomiting Ann. Pharmacother., January 1, 2005; 39(1): 77 - 85. [Abstract] [Full Text] [PDF]

				E S Antonarakis and R D W Hain Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice Arch. Dis. Child., September 1, 2004; 89(9): 877 - 880. [Abstract] [Full Text] [PDF]

				A. Ihbe-Heffinger, B. Ehlken, R. Bernard, K. Berger, C. Peschel, H.-G. Eichler, R. Deuson, J. Thodtmann, and F. Lordick The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers Ann. Onc., March 1, 2004; 15(3): 526 - 536. [Abstract] [Full Text] [PDF]

				P. Eisenberg, F. R. MacKintosh, P. Ritch, P. A. Cornett, and A. Macciocchi Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study Ann. Onc., February 1, 2004; 15(2): 330 - 337. [Abstract] [Full Text] [PDF]

				P. J. Hesketh, S. M. Grunberg, R. J. Gralla, D. G. Warr, F. Roila, R. de Wit, S. P. Chawla, A. D. Carides, J. Ianus, M. E. Elmer, et al. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin--The Aprepitant Protocol 052 Study Group J. Clin. Oncol., November 15, 2003; 21(22): 4112 - 4119. [Abstract] [Full Text] [PDF]

				R. de Wit, J. Herrstedt, B. Rapoport, A.D. Carides, G. Carides, M. Elmer, C. Schmidt, J.K. Evans, and K.J. Horgan Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based Chemotherapy J. Clin. Oncol., November 15, 2003; 21(22): 4105 - 4111. [Abstract] [Full Text] [PDF]

				R. M Navari and J. M Koeller Electrocardiographic and Cardiovascular Effects of the 5-Hydroxytryptamine3 Receptor Antagonists Ann. Pharmacother., September 1, 2003; 37(9): 1276 - 1286. [Abstract] [Full Text] [PDF]

				P.-B. Tremblay, R. Kaiser, O. Sezer, N. Rosler, C. Schelenz, K. Possinger, I. Roots, and J. Brockmoller Variations in the 5-Hydroxytryptamine Type 3B Receptor Gene as Predictors of the Efficacy of Antiemetic Treatment in Cancer Patients J. Clin. Oncol., June 1, 2003; 21(11): 2147 - 2155. [Abstract] [Full Text] [PDF]

				F. M. Schnell Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control Oncologist, April 1, 2003; 8(2): 187 - 198. [Abstract] [Full Text] [PDF]

				R. Kaiser, O. Sezer, A. Papies, S. Bauer, C. Schelenz, P.-B. Tremblay, K. Possinger, I. Roots, and J. Brockmoller Patient-Tailored Antiemetic Treatment With 5-Hydroxytryptamine Type 3 Receptor Antagonists According to Cytochrome P-450 2D6 Genotypes J. Clin. Oncol., June 15, 2002; 20(12): 2805 - 2811. [Abstract] [Full Text] [PDF]

				R. H. Rosen Management of Chemotherapy-Induced Nausea and Vomiting Journal of Pharmacy Practice, February 1, 2002; 15(1): 32 - 41. [Abstract] [PDF]

				D. Campos, J. R. Pereira, R. R. Reinhardt, C. Carracedo, S. Poli, C. Vogel, J. Martinez-Cedillo, A. Erazo, J. Wittreich, L.-O. Eriksson, et al. Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone J. Clin. Oncol., March 15, 2001; 19(6): 1759 - 1767. [Abstract] [Full Text] [PDF]

				J. P. A. Ioannidis, P. J. Hesketh, and J. Lau Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence J. Clin. Oncol., October 19, 2000; 18(19): 3409 - 3422. [Abstract] [Full Text] [PDF]

				R. J. Gralla, D. Osoba, M. G. Kris, P. Kirkbride, P. J. Hesketh, L. W. Chinnery, R. Clark-Snow, D. P. Gill, S. Groshen, S. Grunberg, et al. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., September 1, 1999; 17(9): 2971 - 2971. [Full Text] [PDF]

				A. Junker and G. J Wiedemann Antiemetic guidelines: A cooperation between a non-university hospital (Klinikum Remscheid) and a university center (Medical University of Lubeck) in Germany Journal of Oncology Pharmacy Practice, September 1, 1999; 5(3): 125 - 127. [PDF]

				P. J. Hesketh Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice Oncologist, June 1, 1999; 4(3): 191 - 196. [Abstract] [Full Text]

				R. M. Navari, R. R. Reinhardt, R. J. Gralla, M. G. Kris, P. J. Hesketh, A. Khojasteh, H. Kindler, T. H. Grote, K. Pendergrass, S. M. Grunberg, et al. Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1-Receptor Antagonist N. Engl. J. Med., January 21, 1999; 340(3): 190 - 195. [Abstract] [Full Text] [PDF]

				J. Bubalo Antiemetic guidelines: Oregon Health Sciences University Journal of Oncology Pharmacy Practice, December 1, 1998; 4(4): 181 - 182. [PDF]

				K. L Lenz, E. M Marley, and P. D Hall Guidelines for antiemetic use: Medical University of South Carolina, Hollings Cancer Center Journal of Oncology Pharmacy Practice, December 1, 1998; 4(4): 202 - 204. [PDF]

				J. I. Spector, E. P. Lester, E. M. Chevlen, D. Sciortino, J. H. Harvey, W. Whaley, S. Madajewicz, R. Isaacs, H. D. Homesley, S. Yee, et al. A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy Oncologist, December 1, 1998; 3(6): 432 - 438. [Abstract] [Full Text]